We found that more patients with PD-L1 expression at cutoffs of ≥1% and ≥5% were identified by AI-powered scoring compared with manual scoring in patients with NSCLC, UC, and MEL. This evidence concerns the gene CD274 and non-small cell lung carcinoma.